AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Brachyspira and Intestinal Allergy-like Immune Reactions in Patients With Irritable Bowel Syndrome (IBS)

RecruitingNAAges 18 Years - 70 YearsAllMagnus Simrรฉn
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The aim of this study is to define local immune responses in the GI tract to food antigens in IBS patients, with and without Brachyspira infection, using advanced imaging. We hypothesize that Brachyspira infection can cause IBS symptoms by inducing loss of oral tolerance to dietary antigens through development of food-specific intestinal immune reactions and subsequent development of visceral hypersensitivity. During this study, the investigators will perform confocal laser endomiscroscopy (CLE) and/or colonoscopic antigen provocation test (COLAP) to test to which food items the participants react to. Furthermore, the investigators will perform rectal barostat examination and a sigmoidoscopy without laxatives. The investigators will collect biological samples and the participants will complete several questionnaires.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients with IBS diagnosis according to their treating physician (ROME IV). * Association between intake of food and GI symptoms. * Witnessed written informed consent prior to any study procedures. * Patients who are capable to understand the study and the questionnaires, and to comply with the study requirements. Exclusion Criteria: * Patients with relevant concurrent organic GI disease (inflammatory bowel disease, abdominal cancer), or a major disease such as diabetes, uncontrolled thyroid disease, heart disease, kidney disease, liver disease, and active malignant disease (not those that were in remission at least 5 years). * Patients with a history of bowel surgery (not appendectomy or cholecystectomy) that affects GI motility. * Patients with systemic food allergy as evidenced by positive allergy tests (blood, prick test). * Clinical history of severe allergic reactions. * Patients with concurrent major confounding condition(s) based on the clinician's judgement, e.g. DOMINANT psychiatric disorder, vital depression, alcohol or substance abuse in the last 2 year. * Female patients who are pregnant or lactating (females of fertile age are requested to use a safe contraceptive) at the time of inclusion. * Patients who use or used new medications that affect the GI functioning within 1 month before the start of the study.
๐Ÿ’Š

What it tests

  • Elimination and re-introduction of CLE or COLAP positive food item(s)
๐Ÿ“

Where

1 site
Mag-tarmlab, Dept of Internal Medicine, Sahlgrenska University Hospital
Gothenburg, Sweden
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy